Abstract： Objective To discuss the effect of echinoderm microtubule-associated protein-like 4(EML4)-anaplastic lymphoma kinase(ALK)/breast cancer susceptibility gene 1(BRCA1)gene polymorphism on the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors(EGFR-TKIs)in advanced non-small cell lung cancer and patient prognosis.Methods 83 patients with advanced non-small cell lung cancer were selected,and EML4-ALK and BRCA1 variants of all patients were test-ed,and the disease control rate and 1-year survival rate were compared among different genotypes.Results Among all patients,10 cases were positive for EML4-ALK,including 7 cases of type V1 and 3 cases of type V2.BRCA1 typing included 50 cases of Ser/Gly,20 cases of Ser/Ser,and 13 cases of Gly/Gly.The disease control rate in EML4-ALK-positive patients was not signifi-cantly different from that in negative patients(P＞0.05).The disease control rate among patients with different BRCA1 genotypes was the highest in Ser/Gly,followed by Ser/Ser,and was the lowest in Gly/Gly(P＜0.05).The 1-year progression free survival rate and 1-year overall survival rate yielded no statistical difference between EML4-ALK positive patients and EML4-ALK nega-tive patients(P＜0.05).Ser/Gly patients had a higher 1-year progression-free survival rate than Ser/Ser and Gly/Gly patients(P＜0.05),while the 1-year progression-free survival rate demonstrated no statistical difference between Ser/Ser patients and Gly/Gly patients(P＞0.05).The 1-year overall survival rate was higher in Ser/Gly patients than in Ser/Ser patients(P＜0.05),while there was no significant difference in comparison between Ser/Gly patients and Gly/Gly patients(P＞0.05).The 1-year o-verall survival rate of Ser/Ser patients showed no significant difference with that of Gly/Gly patients(P＞0.05).Conclusion The efficacy and prognosis of patients with advanced non-small cell lung cancer receiving EGFR-TKIs therapy are not affected by EML4-ALK positivity but by BRCA1 gene polymorphism.